E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Molecular Imaging and Treatment Monitoring of Cancer"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 10 March 2018

Special Issue Editor

Guest Editor
Prof. Dr. Samuel Achilefu

Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA
Website | E-Mail
Interests: cancer imaging and therapy; fluorescence lifetime; molecular imaging agents; multimodal imaging; nanomedicine; near-infrared fluorescent dyes; nuclear imaging, peptides; spectroscopy

Special Issue Information

Dear Colleagues,

The evolution of molecular imaging over the past two decades has ushered in new approaches to detect, treat, and monitor the treatment response of pathophysiologic conditions in animal models of human diseases. In particular, the application of these methods to cancer imaging and therapy holds great promise in improving the accuracy of cancer detection and the efficacy of targeted therapies, as well as reporting the functional status and state of the disease. As a result, new molecular imaging probes and methods are expected to provide diagnostic information beyond what is currently available in clinics. Thus, in addition to reporting the presence of cancer, emerging molecular imaging probes could also determine tumor viability, type, stage, heterogeneity, and potential response to treatment. The goal of this Special Issue is to assemble pertinent research papers, perspectives, and concise reviews that illustrate how molecular imaging can overcome current challenges in cancer detection, staging, and response to therapy. Manuscripts that cover the diverse molecular imaging platforms are welcome. These include optical, nuclear, ultrasonic, magnetic resonance, and multimodal imaging probes and methods. Examples of research work that have advanced from bench to bedside are also encouraged, including the challenges and opportunities in obtaining regulatory approval to use molecule probes in human patients.

Prof. Dr. Samuel Achilefu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cancer imaging
  • Imaging function status of cancer
  • Imaging hypoxic and metabolic state of cancer
  • Imaging tumor microenvironment
  • Magnetic resonance imaging probes and methods
  • Monitoring treatment response
  • Multimodal imaging probes and methods
  • Nanoparticles in cancer imaging and therapy
  • Nuclear imaging agents and methods
  • Optical imaging probes and methods
  • Photoacoustic imaging probes and methods
  • Translation of new molecular probes to clinic
  • Ultrasonic imaging probes and methods

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle Early Response Monitoring Following Radiation Therapy by Using [18F]FDG and [11C]Acetate PET in Prostate Cancer Xenograft Model with Metabolomics Corroboration
Molecules 2017, 22(11), 1946; doi:10.3390/molecules22111946
Received: 6 October 2017 / Revised: 6 November 2017 / Accepted: 8 November 2017 / Published: 10 November 2017
PDF Full-text (4207 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
We aim to characterize the metabolic changes associated with early response to radiation therapy in a prostate cancer mouse model by 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) and [11C]acetate ([11C]ACT) positron emission tomography, with nuclear magnetic resonance (NMR) metabolomics
[...] Read more.
We aim to characterize the metabolic changes associated with early response to radiation therapy in a prostate cancer mouse model by 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) and [11C]acetate ([11C]ACT) positron emission tomography, with nuclear magnetic resonance (NMR) metabolomics corroboration. [18F]FDG and [11C]ACT PET were performed before and following irradiation (RT, 15Gy) for transgenic adenocarcinoma of mouse prostate xenografts. The underlying metabolomics alterations of tumor tissues were analyzed by using ex vivo NMR. The [18F]FDG total lesion glucose (TLG) of the tumor significant increased in the RT group at Days 1 and 3 post-irradiation, compared with the non-RT group (p < 0.05). The [11C]ACT maximum standard uptake value (SUVmax) in RT (0.83 ± 0.02) and non-RT groups (0.85 ± 0.07) were not significantly different (p > 0.05). The ex vivo NMR analysis showed a 1.70-fold increase in glucose and a 1.2-fold increase in acetate in the RT group at Day 3 post-irradiation (p < 0.05). Concordantly, the expressions of cytoplasmic acetyl-CoA synthetase in the irradiated tumors was overexpressed at Day 3 post-irradiation (p < 0.05). Therefore, TLG of [18F]FDG in vivo PET images can map early treatment response following irradiation and be a promising prognostic indicator in a longitudinal preclinical study. The underlying metabolic alterations was not reflected by the [11C]ACT PET. Full article
(This article belongs to the Special Issue Molecular Imaging and Treatment Monitoring of Cancer)
Figures

Figure 1

Back to Top